Exosomes, post‑laser gel to IV drip.

The trial: "A 12-week prospective, double-blind, randomized, split-face trial was performed. A total of 25 patients received 3 consecutive treatment sessions of fractional CO2 laser to the whole face … one side of the face was treated with adipose tissue stem cell-derived exosomes gel and the other side was treated with control gel. Adipose tissue stem cell-derived exosomes-treated sides had achieved a significantly greater improvement than the control sides at the final follow-up visit (percentage reduction in échelle d'évaluation clinique des cicatrices d'acné scores: 32.5 vs 19.9%, p < 0.01). Treatment-related erythema was milder, and post-treatment downtime was shorter" (Kwon 2020). The fresh-scar cousin: in ten people with chest scars from rib-cartilage harvest, the half treated with an adipose exosome product improved in pliability, pigmentation and relief against the half treated with hyaluronic acid, with one-year photographs showing "superior improvements in scar height and thickness on the exosome-treated side" (Jeong 2026). The comparators: microneedling alone improves acne scars in a meta-analysis of 12 randomised trials (Shen 2022), and adding PRP to it roughly triples the odds of a better-than-50% improvement, odds ratio 2.97, across 14 studies and 472 patients (Kang 2021).

Emerging: one 25-patient trial with a clear result is exactly what the tier describes, and the microneedling and biostimulator guides grade microneedling with PRP moderate on its 14 studies. The honest advice for an acne-scar patient is the laser or the needling first, PRP as the evidence-based add-on, and exosomes as the add-on for someone who cannot or will not have blood drawn — at a surcharge that reflects one trial.

The comparison: "Participants with mild to moderate photoaging underwent three radiofrequency microneedling treatments with PRP and topical exosomes each applied to one half of the face … Both exosomes and PRP equally improved wrinkling, dyschromia, erythema, texture, and overall skin appearance. Histological analysis confirmed increased collagen I and glycosaminoglycans, without significant differences between treatment arms" — a non-inferiority design with no untreated side (Estupiñan 2025). The controlled trial: "At week 12, wrinkle improvement was 12.59 (2.58) points on the RFMN+EV side and 9.28 (2.35) points on the RFMN side, giving a paired mean difference of 3.32 points (95% CI: 2.55-4.08)", with the authors' caveat that "the unblinded design, 12-week follow-up, and absence of histologic or molecular biomarkers require cautious interpretation" (Yen 2026). The series: nine women, split-face, exosomes with microneedling, CO2 or picosecond laser — "exosome-treated sides showed greater improvements in texture, hydration, elasticity, and pigmentation", least with the picosecond laser, "possibly due to pinpoint bleeding reducing exosome absorption" (Vitale 2025); six subjects with rose stem-cell exosomes after needling radiofrequency, greater wrinkle reduction at one and three months (Huang 2026). The systematic review of the combination: eight studies of 3 to 60 participants, "more evidence is required before we can ascertain the safety profile and efficacy profile" (Dhaliwal 2026).

Emerging, and the reader should notice what the comparator was in every study: the same device without the vial, or PRP. Nobody has tested exosomes against a bland occlusive after the device, which is what the untreated side of a split-face gets anyway, and the collagen on biopsy in the PRP comparison rose equally on both sides because the needling made it. The tightening, microneedling and resurfacing guides grade the devices themselves.

The reviews: "Eleven studies included: two RCTs, three retrospective studies, three prospective single-arm studies, one case series, and two case reports … MSC-derived exosomes from adipose tissue, placenta, hair follicles, bone marrow, foreskin, and umbilical cord having substantial increases in hair density (9.5 to 35 hairs/cm²) and hair thickness (up to 13.01 µm) … no serious adverse events were noted. The greatest level of evidence came from RCTs with adipose- and plant extract-derived exosome formulation. However, heterogeneity in design and outcome limited direct comparisons" (Al Ameer 2025); "EV therapy, though less studied (3 studies, 89 patients), showed hair count increases of 28% and density gains up to 45% in certain subgroups, with higher responses in early-stage AGA" (Behrangi 2026); "Topical ADSC-Exo has been tried successfully in 39 androgenetic alopecia patients demonstrating significant increases in hair density and thickness" among 16 studies of which 15 were preclinical (Gupta 2023); "One hundred twenty-five patients received an exosome treatment for hair loss. Side effects were rare. However, in the broader field of dermatology, at least 10 serious adverse events have been reported" (Queen & Avram 2025); of 27 studies in the stem-cell exosome hair literature, three were clinical (Poddar 2025). The open-label study: 30 men and women, an "Exosome Regenerative Complex" applied after microneedling on days 0, 30, 60 and 90, "significantly increased terminal and vellus hair counts (P<0.0001) and decreased hair shedding on day 120", no control group, manufacturer-affiliated (Ablon 2025). The comparators: PRP raised density at three and six months against placebo in nine randomised trials (Zhang 2023) — "MD, 25.6 hairs/cm²" against saline, "low quality due to inconsistency and risk of bias" (Cruciani 2023) — and in the network meta-analysis of 27 trials, 5% minoxidil plus microneedling ranked first (SUCRA 95.8%), ahead of minoxidil alone, PRP alone and microneedling alone (Gupta 2023b).

Emerging here for the topical-after-needling use; the hair loss guide grades exosome and "stem-cell" scalp injections limited, and so does this page in the injection row. The order of evidence for a thinning scalp is unchanged: minoxidil, the antiandrogen where appropriate, microneedling, then PRP — with an exosome course as an add-on that costs more than all four and has eleven small studies behind it.

The wound trial: 110 people with persistent diabetic foot ulcers randomised to weekly topical Wharton's-jelly exosomes with standard care, standard care alone, or the vehicle; "the treated group's mean time to fully recover was 6 weeks (range: 4-8 weeks), while the controls were 20 weeks (range: 12-28 weeks)" (Kishta 2025). The phase I trial: clinical-grade platelet vesicles injected into healthy volunteers were "safe and well tolerated", and "all wounds healed rapidly and completely and no difference in time to wound closure of the treated and untreated wounds was observed at the single dose tested" (Johnson 2023). The scar study: ten rhinoplasty patients, chest incision scars four months old split into exosome and hyaluronic-acid halves — pliability improved "beginning at week 3 and persisting through week 8", pigmentation improved on observer scoring, and "one-year follow-up photographs confirmed superior improvements in scar height and thickness on the exosome-treated side" (Jeong 2026). The animal literature: 68 studies in which small vesicles "promoted skin regeneration in diabetic and non-diabetic animal models … regardless of cell source, production protocol and disease model", with risk of bias "uncertain for most studies due to insufficient reporting" (Al-Masawa 2022).

Emerging, and the most interesting row on the page: a real randomised trial in a real disease, run as medicine rather than as aesthetics, is what the field needs and what the diabetic-ulcer study is. It does not license the clinic vial — a different product, a different dose, a different wound — but it is the reason the science is worth watching. For a cosmetic scar, silicone gel, sun protection and the resurfacing guide's lasers remain the treatments with evidence.

The evidence is a sentence: "Treatment-related erythema was milder, and post-treatment downtime was shorter on the applications of human adipose tissue stem cell-derived exosomes-treated side" (Kwon 2020), supported by "texture, pore, erythema, melanin, hydration, and GAIS outcomes numerically favored RFMN+EV, while local reactions were transient and predominantly mild" (Yen 2026) and by the nine-woman series (Vitale 2025). The mechanism is plausible — anti-inflammatory and pro-angiogenic cargo, shown in the laboratory for both adipose and umbilical sources (Ponnikorn 2026) — and the reviews list wound healing as the best-supported preclinical effect (Yu 2024; Xiong 2021).

Emerging, and the cheapest row to test at home: the difference the trial reports is a matter of days, on the side of a face that also healed fine without it. The post-laser protocol in the resurfacing guide — occlusive ointment, no picking, strict sun avoidance — is what the control side received, and it is the part that matters.

The study: "In the clinical application study, 60 patients with melasma treated in our department were divided into four groups. NAFL combined with normal saline treatment was used for Group A. Microneedles, NAFL, and PBASM combined with hUCMSC-Exos treatments were used for Groups B, C, and D … compared with Group A, Groups B, C, and D showed significantly improved therapeutic effect and patient satisfaction (p < 0.05), and there was no significant difference among Groups B, C, and D" — and, in the animal arm, "hUCMSC-Exos can penetrate the deep dermis under microneedles, NAFL, and PBASM treatments" (Wang 2023). The mechanism: "both reduced melanogenesis without altering melanocyte viability" in the ex vivo skin model (Ponnikorn 2026); the scar study recorded pigmentation improving on observer scoring from week three (Jeong 2026); the rose-exosome case series reports hyperpigmentation and melasma among its eight cases (Majewska 2025). The reviews list melasma among the indications with "clinical efficacy" while noting the standardisation gap (Nahm 2025).

Emerging: the 60-patient comparison is not described as randomised and the exosome groups also had the extra device. The dark spots guide carries the ladder that works — iron-oxide tinted sunscreen, hydroquinone and the triple cream, tranexamic acid, then the lasers — and the sunscreen guide the base under all of it.

The sensitive-skin study: 22 women, exosomes from primary mesenchymal stem cells characterised to the ISEV standard, 28 days; "scores of objective symptoms including roughness, scales, erythema, and subjective symptoms including tension, burning, or itching, were improved after 7-, 14-, and 28- day using hMSC-exosomes. TEWL, hydration, sebum, pH, and a* values were tended to return to the level of healthy skin" — no control group (Ye 2022). The psoriasis study: a Wharton's-jelly secretome and hyaluronic-acid sponge containing exosomes of 164 ± 87 nm; "in a 30-day efficacy study, 12 patients with bilateral psoriasis exhibited up to a 33% reduction in mPASI scores and a 41% decrease in plaque size", with transepidermal water loss down 30% (Elgueta 2025). The mechanism is the best-documented part: umbilical-cord exosomes "demonstrated stronger immunomodulatory activity and more pronounced SASP reduction in ultraviolet-damaged skin" in the laboratory (Ponnikorn 2026), and the mechanism reviews cover psoriasis, dermatitis and vitiligo (Yu 2024).

Emerging: the effects are on symptom scores in studies without placebo arms, in conditions where a placebo cream moves symptom scores too. The facial redness guide grades the treatments with trials, and an exosome serum for a barrier problem is, in Europe, a plant-vesicle cosmetic at best.

The barrier: "the molecular weight (MW) of a compound must be under 500 Dalton to allow skin absorption. Larger molecules cannot pass the corneal layer" (Bos 2000); labelled exosomes reached the deep dermis only under microneedling, laser or plasma (Wang 2023); the rose-exosome investigators note that "limited penetration restricts clinical utility" (Huang 2026). The serum studies: "This prospective, single-arm, non-randomized, longitudinal study" of a platelet extract found imaging "skin health score" improved at six weeks (Proffer 2022); the follow-up, "prospective, single-arm, non-randomized, evaluator-blinded", enrolled 56 people for 12 weeks, "87.3% of subjects reported improvement" and "histology revealed a significant increase in collagen fibril thickness" — with no vehicle arm to show what twelve weeks of moisturiser and sun protection do (Wyles 2024); bovine milk vesicles applied by 31 volunteers for 28 days were reported to preserve moisture and reduce wrinkles (Lu 2024). The genre: growth-factor preparations across 33 studies and 1,180 participants gave "a modest improvement in skin texture (median < 50%), fine lines/wrinkles (median < 35%)" against baseline, and "three comparative RCTs showed no statistically significant differences between treatments" (Quinlan 2023); the blinded split-face trial of a deer stem-cell conditioned-media cream: "Blinded investigator assessments did not detect any statistically significant differences between the two halves of the face" (Alhaddad 2019). The reviews' verdict on topical exosomes: "generally considered safe in humans on intact skin", with no consensus on benefit (Vyas 2023).

Limited, as the serums guide grades the whole "regenerative" shelf. Safe on intact skin, expensive, and unable to reach the cells it is sold to instruct; the money belongs in a retinoid, a sunscreen and a vitamin C serum, all of which have blinded trials.

The regulators: "There are currently no FDA-approved exosome products" and the notification followed "multiple recent reports of serious adverse events experienced by patients in Nebraska" (FDA 2019); in Europe, a product administered to treat is a medicinal product under the ordinary or advanced-therapy frameworks and none is licensed (Limongi 2026). The harms: "Adverse events were uncommon but included granulomas, necrosis, and allergic reactions post-injection" (Wang 2026); "in the broader field of dermatology, at least 10 serious adverse events have been reported" (Queen & Avram 2025); "clinical studies are lacking, and there are substantial safety concerns, such as the potential risk of infections, unwanted inflammatory response, and promotion of malignancy" (Mahmoud 2025). The one lawful injection study — clinical-grade platelet vesicles in a phase I trial — was designed to test safety, found it, and found no healing benefit (Johnson 2023). The society position: "a global industry of direct-to-consumer offerings of prematurely commercialized cell and cell-based products with unknown safety and efficacy profiles" (Ikonomou 2023).

Limited, as the hair loss, collagen loss, biostimulator and longevity clinics guides grade the injections and drips. The distinction this whole page turns on: on the skin after a device, an exosome is an unproven cosmetic; in a syringe, it is an unlicensed medicine of unknown content, and the case reports are of the second kind.

The bench: "Both exosome types increased fibroblast proliferation and reduced senescence. AD-MSC exosomes showed higher vascular endothelial growth factor (VEGF) content, driving angiogenesis and greater collagen and hyaluronic acid production. UC-MSC exosomes … demonstrated stronger immunomodulatory activity and more pronounced SASP reduction" — in dermal fibroblasts and skin explants, with retinoic acid as the reference control (Ponnikorn 2026); the plant-vesicle literature on photoaging is likewise cellular and murine (Dong 2025). The people: collagen I rose on biopsy after radiofrequency microneedling "without significant differences between treatment arms" of exosomes and PRP (Estupiñan 2025); the serum histology had no control (Wyles 2024). The claims: "27% of claims were misleading" and "most companies relying on vague and promotional language" (Rahman 2025c); "the field of regenerative aesthetics lacks the necessary scientific rigour and regulatory compliance to be recognized as a legitimate medical specialty" (Rahman 2025b); and the reporting standard's caution that exosome-specific activity claims "remain difficult to support experimentally" (Théry 2018).

Limited, in the site's sense of marketing running ahead of measurement. The collagen that has been measured on human biopsies belongs to tretinoin (the retinoids guide), to the poly-L-lactic acid and calcium hydroxylapatite biostimulators (the biostimulator guide) and to the fractional lasers (the resurfacing guide).

The grey-hair study: "This cross-sectional observational study enrolled 10 patients with visible gray or white hair who were treated with rose stem cell-derived exosomes (RSCEs) using various procedures … Repigmentation was observed after an average of 2.4 ± 0.7 sessions and was maintained for 4.7 ± 1.9 months … 60% achieving a higher-grade response" — an observational series with no comparator, from the group that also published a single case of rose exosomes delivered by electroporation for pattern hair loss (Lueangarun 2025; Lueangarun 2024). The rose-exosome case series covers eight patients across atopic dermatitis, pigmentation, scarring, wounds and "antiaging concerns" and "emphasizes the need for further randomized and controlled clinical trials" (Majewska 2025). For the remaining menu items there is no human study to cite.

Limited. The cellulite, dark circles, neck and lips guides grade what works for each; none of them has an exosome row because there is nothing to grade.